Page last updated: 2024-08-25

alantolactone and ER-Negative PR-Negative HER2-Negative Breast Cancer

alantolactone has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, X; Cui, R; Dai, X; Huang, X; Liang, G; Rajamanickam, V; Wang, C; Wang, O; Yin, C; Zhang, X; Zhao, C; Zhou, Q; Zhu, W; Zou, P1

Other Studies

1 other study(ies) available for alantolactone and ER-Negative PR-Negative HER2-Negative Breast Cancer

ArticleYear
Alantolactone promotes ER stress-mediated apoptosis by inhibition of TrxR1 in triple-negative breast cancer cell lines and in a mouse model.
    Journal of cellular and molecular medicine, 2019, Volume: 23, Issue:3

    Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Endoplasmic Reticulum Stress; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lactones; Mice, Inbred BALB C; Mice, Nude; Reactive Oxygen Species; Sesquiterpenes, Eudesmane; Thioredoxin Reductase 1; Thioredoxin-Disulfide Reductase; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2019